A New Hope for EPI: Blackstone's $250M Push for a One-Pill Solution

NEW YORK, NY – May 07, 2026 – Private equity giant Blackstone Life Sciences has announced a landmark $250 million investment in Anagram Therapeutics, a clinical-stage biopharmaceutical company, to propel a potentially revolutionary treatment for Exocrine Pancreatic Insufficiency (EPI). The investment is aimed squarely at advancing ANG003, a novel oral enzyme therapy that promises to dramatically slash the debilitating pill burden for patients and disrupt a multi-billion-dollar market currently grappling with chronic supply shortages.

For thousands of people living with conditions like cystic fibrosis (CF) and pancreatic cancer, EPI means their bodies cannot produce enough digestive enzymes to absorb nutrients. The current standard of care forces them into a grueling daily routine of swallowing up to 40 capsules of pig-derived enzymes. Anagram’s ANG003 aims to replace that handful of pills with a single, more effective tablet taken with each meal, representing a monumental leap forward in quality of life.

"We believe Anagram is well positioned to transform the treatment of pancreatic insufficiency, especially in patients of all ages who suffer from cystic fibrosis," said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences, in a statement announcing the deal. "This is an excellent case study of our ownership strategy where we bring scale capital, deep domain expertise, and hands-on engagement to help address large unmet medical needs."

A New Paradigm for Patient Treatment

The daily reality for someone with severe EPI is a life dictated by medication schedules. The high pill burden associated with current pancreatic enzyme replacement therapies (PERT) is not just inconvenient; it significantly impacts adherence, mental health, and overall well-being. Despite taking dozens of pills, many patients still suffer from malnutrition, gastrointestinal distress, and a diminished quality of life.

"Patients today also face an enormous, disruptive pill burden, taking up to 40 pills a day to treat their EPI," noted Kiran Reddy, MD, a Senior Managing Director at Blackstone Life Sciences. "We expect ANG003 to only require one tablet per meal which we believe will positively impact compliance and quality of life."

ANG003 is a new class of recombinant, broad-spectrum enzyme therapy, engineered in a lab rather than extracted from animal glands. It contains a combination of lipase, protease, and amylase to aid the digestion of fats, proteins, and carbohydrates. Its design aims for immediate activity and stability within the gastrointestinal tract, potentially offering more consistent and effective nutrient absorption than its porcine-derived counterparts.

The development is particularly critical for the cystic fibrosis community. An estimated 80-90% of CF patients develop EPI, and managing digestive health is a cornerstone of their overall care, directly impacting lung function and life expectancy. The Cystic Fibrosis Foundation recognized this need early, providing over $30 million in foundational funding that paved the way for ANG003's development to date.

Disrupting a Strained Market

Blackstone's quarter-billion-dollar investment is not just a bet on better science; it's a strategic move into a $2 billion U.S. market that is showing significant signs of strain. The entire global supply of approved PERT medications, including the market leader Creon, is derived from pig pancreases. This single-source dependency has created a fragile supply chain.

In recent years, patients and healthcare providers have been plagued by severe, ongoing global shortages of PERT products. Manufacturing constraints and limited raw material availability have left pharmacies scrambling and patients rationing medication. Some reports indicate these shortages could persist until 2026 or 2027, forcing patients to switch brands or go without, leading to weight loss, malnutrition, and severe anxiety. A recent survey from the Cystic Fibrosis Trust revealed that 43% of people with CF experienced a significant or severe impact on their health due to the shortages.

ANG003, as a non-porcine, lab-created product, is immune to these agricultural and supply chain vulnerabilities. Its development offers a path to a stable, reliable, and scalable supply of essential medicine, addressing one of the most pressing crises in EPI treatment. By offering a potentially superior clinical profile combined with supply chain security, ANG003 is poised to fundamentally challenge the existing market leaders.

The Science and the Path Forward

The $250 million infusion from Blackstone will accelerate ANG003 through its critical final stages of development, regulatory approval, and commercial launch. Anagram is building on a foundation of promising early results. The company recently completed a Phase 1 clinical study (ANG003-22-101) in adults with CF-related EPI, which demonstrated that the therapy was generally well-tolerated.

With that positive data in hand, Anagram is now initiating an international Phase 2 study. This crucial trial will directly compare the safety and efficacy of ANG003 against Creon, the current standard of care. Success in this head-to-head trial would provide powerful evidence for its adoption by clinicians and patients worldwide.

"We believe the clinical data generated from the ANG003-22-101 study in patients with EPI due to CF is compelling and has the potential to be a transformational treatment for people living with EPI," said Robert Gallotto, President and CEO of Anagram. He also expressed gratitude to the Blackstone team and the Cystic Fibrosis Foundation for their pivotal support in advancing the therapy.

This journey from foundational research to a large-scale investment highlights a successful model for developing treatments for rare diseases. The initial, high-risk funding from a patient advocacy group like the CF Foundation de-risked the asset, proving its potential and making it an attractive candidate for a major institutional investor like Blackstone to carry across the finish line.

This substantial backing from one of the world's leading life science investors validates the transformative potential of Anagram's technology. It represents a confluence of patient-centric innovation and strategic market disruption, providing a powerful tailwind for a therapy that could redefine the standard of care for a long-neglected patient population. As the international Phase 2 trial gets underway, the entire EPI community will be watching with hope for a future free from the burden of countless pills and the uncertainty of an unstable supply chain.